IGFBP3 and colorectal carcinoma: Conversely, it is also possible that this event is merely a consequence of CIMP, and IGFBP3 methylation consequently serves as a surrogate marker of this phenotype and may be an important determinant of poor responses to 5-FU-based adjuvant chemotherapy in CRC, as previously shown by our laboratory [7].